

IN THE CLAIMS

1. (currently amended) A method of treating a subject~~treatment~~, comprising:
 - a) providing:
 - i) a subject with having a symptom of inflammatory bowel disease or short bowel syndrome, and
 - ii) a therapeutic composition comprising an angiotensin converting enzyme inhibitor, and;
 - b) administering said composition to said subject under conditions such that the severity of inflammatory bowel disease or short bowel syndromesaid symptom is reduced in said subject.
2. (original) The method of Claim 1, wherein said subject is a mammal.
3. (original) The method of Claim 2, wherein said mammal is a human.
4. (original) The method of Claim 1, wherein the route of administration of said composition is selected from intravenously, orally, parenterally, topically, and rectally.
5. (original) The method of Claim 1, wherein said composition further comprises a transdermal patch.
6. (canceled)
7. (currently amended) The method of Claim 1, wherein said angiotensin converting enzyme inhibitor is selected from the group consisting of alacepril, benazepril (~~Lotensin~~), captopril (~~Capoten~~), cilazapril, ceranapril, delapril, enalapril (~~Vasotec~~), enalaprilat, fosinopril (~~Monopril~~), fosinoprilat, imidapril, lisinopril (~~Prinivil~~, ~~Zestril~~), moexipril (~~Univase~~), perindopril (~~Aceon~~), perindoprilat, quinapril (~~Aceupril~~), quinaprilat, ramipril (~~Altace~~), saralasin acetate, spirapril, temocapril, trandolapril (~~Mavik~~), fasidotrilat~~Bioproject BP1-137~~, beclometasone dipropionate~~Chiesi CHF-1514~~, ~~Fisons FPL-66564~~, idrapril, ~~Marion Merrell Dow MDL-100240~~,

and Servier-S-5590.

8-17. (cancelled)

18. (new) The method of Claim 1, wherein said administering said composition reduces the histologic colitis score of said subject.

19. (new) The method of Claim 1, wherein said administering said composition reduces the presence of heme positive stools in said subject.

20. (new) The method of Claim 1, wherein said administering said composition prevents loss of body weight in said subject.

21. (new) The method of Claim 1, wherein said administration decreases the clinical severity of colitis in said subject.